Table 2.

Adverse events

Adverse Event	Enzalutamide+Prostvac (n=20)			Enzalutamide alone (n=18)			Total for all patients (n=38)
	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3	Grade1	Grade 2	Grade 3
Injection Site Reaction	14 (70%)	4 (20%)	0	0	0	0	14 (37%)	4 (11%)	0
Flu-like Symptoms	6 (30%)	0	0	0	0	0	6 (16%)	0	0
Fatigue/Lethargy	14 (70%)	4 (20%)	0	13 (72%)	3 (17%)	0	27 (71%)	7 (18%)	0
Breast Pain/Nipple Tenderness	17 (85%)	0	0	14 (78%)	0	0	31 (81%)	0	0
Gynecomastia	6 (30%)	1 (5%)	0	8	1 (6%)	0	14 (37%)	2 (5%)	0
Myalgia	4 (20%)	0	0	1 (6%)	0	0	5 (13%)	0	0
AST/ALT Elevation	0	0	1 (5%)	3 (17%)	0	1 (6%)	3 (8%)	0	2 (5%)
Anorexia	5 (20%)	0	0	2 (11%)	0		7 (39%)	0	0
Dizziness	3 (15%)	1 (5%)	0	2 (11%)	2 (11%)	0	5 (28%)	3 (8%)	0
Headache	5 (25%)	1 (5%)	0	1 (6%)	0	0	6 (33%)	1 (3%)	0
Hypertension	0	1 (5%)	0	1 (6%)	1 (6%)	0	1 (6%)	2 (5%)	0
Hot Flashes	4 (20%)	1 (5%)	0	2 (11%)	0	0	6 (16%)	1 (3%)	0
Memory Impairment	3 (15%)	0	0	1 (6%)	0	0	4 (11%)	0	0
Anemia	6 (30%)	0	0	4 (22%)	0	0	10 (26%)	0	0
Decreased White Blood Cells	5 (25%)	2 (10%)	0	3 (17%)	0	0	8 (31%)	2 (5%)	0
Decreased Libido	3 (15%)	0	0	1 (6%)	0	0	4 (22%)	0	0